Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Jay Barth sold 30,000 shares of the business’s stock in a transaction on Monday, July 27th. The stock was sold at an average price of $15.05, for a total value of $451,500.00. Following the transaction, the insider now directly owns 193,204 shares of the company’s stock, valued at $2,907,720.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Jay Barth also recently made the following trade(s):

  • On Thursday, July 9th, Jay Barth sold 44,447 shares of Amicus Therapeutics stock. The stock was sold at an average price of $15.92, for a total value of $707,596.24.
  • On Tuesday, July 7th, Jay Barth sold 178,988 shares of Amicus Therapeutics stock. The stock was sold at an average price of $15.90, for a total value of $2,845,909.20.
  • On Monday, June 29th, Jay Barth sold 30,000 shares of Amicus Therapeutics stock. The stock was sold at an average price of $15.51, for a total value of $465,300.00.
  • On Wednesday, June 17th, Jay Barth sold 1,904 shares of Amicus Therapeutics stock. The stock was sold at an average price of $13.47, for a total value of $25,646.88.

Amicus Therapeutics stock opened at $14.68 on Friday. Amicus Therapeutics, Inc. has a fifty-two week low of $6.25 and a fifty-two week high of $16.13. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.45 and a quick ratio of 4.31. The stock has a 50-day simple moving average of $14.63 and a 200-day simple moving average of $11.55.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.07). The firm had revenue of $60.53 million during the quarter, compared to analysts’ expectations of $57.21 million. Amicus Therapeutics had a negative net margin of 155.73% and a negative return on equity of 63.24%. On average, research analysts anticipate that Amicus Therapeutics, Inc. will post -1.07 earnings per share for the current fiscal year.

A number of analysts have issued reports on FOLD shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Amicus Therapeutics in a report on Tuesday, June 16th. Chardan Capital reaffirmed a “hold” rating and set a $12.50 price target on shares of Amicus Therapeutics in a report on Saturday, May 9th. SVB Leerink reaffirmed a “market perform” rating and set a $19.00 price target on shares of Amicus Therapeutics in a report on Tuesday, May 19th. BTIG Research started coverage on Amicus Therapeutics in a report on Tuesday, June 16th. They set a “buy” rating and a $19.00 price target for the company. Finally, BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, June 30th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $19.83.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its stake in Amicus Therapeutics by 1.8% during the 1st quarter. BlackRock Inc. now owns 21,239,016 shares of the biopharmaceutical company’s stock valued at $196,248,000 after acquiring an additional 382,909 shares during the last quarter. Janus Henderson Group PLC raised its stake in Amicus Therapeutics by 8.1% during the 1st quarter. Janus Henderson Group PLC now owns 11,625,924 shares of the biopharmaceutical company’s stock valued at $107,423,000 after acquiring an additional 867,308 shares during the last quarter. State Street Corp raised its stake in Amicus Therapeutics by 1.2% during the 1st quarter. State Street Corp now owns 11,129,151 shares of the biopharmaceutical company’s stock valued at $102,833,000 after acquiring an additional 132,427 shares during the last quarter. Nuveen Asset Management LLC raised its stake in Amicus Therapeutics by 92.8% during the 4th quarter. Nuveen Asset Management LLC now owns 4,154,771 shares of the biopharmaceutical company’s stock valued at $40,468,000 after acquiring an additional 2,000,176 shares during the last quarter. Finally, Deutsche Bank AG raised its stake in Amicus Therapeutics by 153.1% during the 1st quarter. Deutsche Bank AG now owns 4,121,255 shares of the biopharmaceutical company’s stock valued at $38,080,000 after acquiring an additional 2,492,623 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

See Also: Technical Indicators – What is a Golden Cross?

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.